Neuromyelitis Optica Spectrum Disorder: Management Updates and Challenging Clinical Cases

Neuromyelitis optica spectrum disorder (NMOSD) is a rare, relapsing, autoimmune disease of the central nervous system that mainly manifests through recurrent attacks of optic neuritis and longitudinally extensive transverse myelitis. NMOSD is often misdiagnosed in the early stages, but the integration of newer diagnostic criteria may assist in an earlier and more accurate differential diagnosis. Until recently, treatment options for NMOSD have been limited―but several approved biologic therapies have now demonstrated efficacy and safety in these patients. In this CE activity, experts in the field will review evidence-based criteria for diagnosis NMOSD as well as risk factors associated with relapse frequency and prognosis, and evaluate therapeutic options based on the latest efficacy and safety data, along with their ability to control acute attacks and prevent future relapses.